Fondazione Ricerca Traslazionale

This study tests whether adding a cancer vaccine (OSE2101) to an immunotherapy drug (cemiplimab) can better clear tumor DNA from the blood of people with advanced lung cancer. About 160 adults with a specific immune type (HLA-A2) who have not worsened after initial treatment will…

This study tests a combination of the targeted drug amivantamab plus a single chemotherapy drug in people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon20 insertion). Participants must not have had prior treatment and must be unable to receive st…

This study tests a combination of chemotherapy and immunotherapy (tislelizumab) given before surgery for people with stage III non-small cell lung cancer that is PD-L1 positive. The goal is to see if this approach helps more patients have successful surgery to remove all cancer. …

This study tests whether adding immune drugs (durvalumab and olaparib) to standard chemotherapy can help people with stage III non-small-cell lung cancer whose cancer has returned after initial treatment. About 176 adults will be split into groups based on when their cancer progr…

This study is for adults with non-small cell lung cancer (NSCLC) who are about to start immunotherapy. Researchers want to understand how the body makes antibodies against the immunotherapy drugs themselves. By analyzing blood samples from 270 participants, they hope to learn mor…